N,N',N'',N'''- tetra(1,2- dihydro- 1- hydroxy- 2- oxopyridine- 6- carbonyl)- 1,5,10,14- tetraazatetradecane
structure given in first source
Also Known As:
3,4,3-LIHOPO
Networked: 5
relevant articles (2 outcomes,
0 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
Related Diseases
1. | Wounds and Injuries (Trauma)
01/01/2000
- " Efficacy of 3,4,3-LIHOPO for reducing neptunium retention in the rat after simulated wound contamination." 02/01/1995
- " 4. It is concluded that 3,4,3-LIHOPO represents, potentially, a considerable advance on DTPA, the current agent of choice for the treatment of wounds contaminated by 228Th." 07/01/1993
- " It is concluded that the administration of 3,4,3-LIHOPO represents potentially a most significant advance in the treatment of wound contamination by 238Pu and 241Am by chelating agents." 12/01/1995
- " Efficacy of 3,4,3-LIHOPO for enhancing the excretion of plutonium from rat after simulated wound contamination as a tributyl-n-phosphate complex." 07/01/1996
- " The effect of a siderophore analogue 3,4,3-LIHOPO has been investigated in rat after intramuscular injection of 238Pu, 239Pu and 241Am simulating puncture wounds. "
|
|
Related Drugs and Biologics
Related Therapies and Procedures